HK Stock Market Move | CSPC PHARMA (01093) rose nearly 3% in the morning, Enyitang's new indication received market approval.

CSPC PHARMA (01093) rose nearly 3% in the morning session, and at the time of writing, it was up 2.87% to HK$4.66, with a turnover of HK$252 million. On the news front, CSPC PHARMA announced that its subsidiary, CSPC PHARMA Jushibio Biopharmaceutical Co., Ltd., has obtained approval from the National Medical Products Administration of the People's Republic of China for a new indication for the biological product 3.3 class omalizumab injection (trade name: Enyiqi) developed for the treatment of moderate to severe persistent allergic asthma. This is the second indication approved for Enyiqi in China. Enyiqi is the first domestically produced biosimilar of omalizumab approved for marketing in China under the biological product 3.3 class registration classification. The previously approved indication was for the treatment of adult and adolescent (12 years and older) patients with chronic idiopathic urticaria who have symptoms despite treatment with H1 antihistamines.